2025 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Welcome to the latest of our Eberhard F Mammen award announcements. As noted in previous editorials ([Table 1]), Thieme, the publisher of Seminars in Thrombosis and Hemostasis (STH), has created the “Eberhard F Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly, 2025 represents 17 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as:

Fig. 1 Eberhard F. Mammen (1930–2008).

Table 1 Previous editorials related to Eberhard F Mammen award announcements

1. Favaloro EJ. Welcome to a special issue of Seminars in Thrombosis and Hemostasis—the closing issue for 2008. Semin Thromb Hemost 2008;34:693–696

2. Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930–2008). Semin Thromb Hemost 2008;34:703–708

3. Favaloro EJ. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009;35:1–2

4. Favaloro EJ. Winners of the inaugural Eberhard F. Mammen Award for most popular article. Semin Thromb Hemost 2009;35:587–590

5. Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award Winners. Semin Thromb Hemost 2010;36:469–470

6. Favaloro EJ. Winners of the 2010 Eberhard F. Mammen Award for Most Popular Article during 2008–2009. Semin Thromb Hemost 2010;36(7):685–692

7. Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011;37(5):431–439

8. Favaloro EJ. 2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012;38:425–432

9. Favaloro EJ. 2013 Eberhard F. Mammen award announcements. Semin Thromb Hemost. 39:567–574

10. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2014;40(4):407–412

11. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2014;40(7):718–723

12. Favaloro EJ. 2015 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2015;41(7):673–679

13. Favaloro EJ. 2015 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2015;41(8):809–815

14. Favaloro EJ. 2016 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2016;42(4):325–330

15. Favaloro EJ. 2016 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2017;43(3):235–241

16. Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2017;43(4):357–363

17. Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2018;44(2):81–88

18. Favaloro EJ. 2018 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2018;44(3):185–192

19. Favaloro EJ. 2018 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2019;45(2):123–129

20. Favaloro EJ. 2019 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2019;45(3):215–224

21. Favaloro EJ. 2019 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2020;46(2):105–113

22. Favaloro EJ. 2020 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2020;46(4):383–392

23. Favaloro EJ. 2020 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2021;47(3):229–237

24. Favaloro EJ. 2021 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2021;47(5):467–476

25. Favaloro EJ. 2021 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2022;48(3):265–273

26. Favaloro EJ. 2022 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2022;48(5):502–513

27. Favaloro EJ. 2023 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2023;49(5):417–426

28. Favaloro EJ. 2022 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2023;49(8):775–782

29. Favaloro EJ. 2024 Eberhard F. Mammen award announcements: part I—most popular articles. Semin Thromb Hemost 2024;50(7):919–932

30. Favaloro EJ. 2023 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2024;50(8):1049–1057

• Most popular article awards: Awarded to the authors of the most popular articles published in STH in the preceding 2 years as captured in the preceding year. The awards are determined by the Editor in Chief on the basis of user statistics from the publisher Thieme e-Journals. Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories: one for “Free Access” articles, and another for a “General Category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “General Category” awards are granted “Free Access” status for these articles thereafter.

• Young investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr Mammen. Up to six cash prizes of US$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. Previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the Senior Editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given historical coronavirus disease 2019 (COVID-19) concerns, some meetings are still held as virtual or hybrid meetings, and accordingly, these meeting presentations can also be considered for the award.

Further details of the awards and the award winners are posted online (<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>), and previous award winner announcements are also available in print ([Table 1]).

It is therefore with great pleasure that we would like to announce the latest winners of the 2025 Eberhard F Mammen awards for the most popular articles from STH, as downloaded in 2024 and as published in the period of 2023 to 2024 inclusive.

2025 “Most Popular” Article Awards

As mentioned, the Most Popular awards are given to the authors of the most popular articles published in STH as determined on the basis of user statistics from the publisher of this journal and covering the preceding 2-year publication period, as captured in the preceding year. Thus, the 2025 “Most Popular” awards are granted to the most popular papers, as downloaded in 2024, and as published in the years 2023 to 2024 inclusive. Previous Eberhard F Mammen award-winning articles are listed in [Table 2]. These articles are currently freely available online (<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>), and no longer qualify for future awards, although some will continue to appear in the most popular download statistics provided by the publisher.

Table 2 Previous most popular award-winning papers

Year	Awarded For
2009	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005;31(4):381–392
2009	Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 2006;32(8):803–809
2010	Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008;34(1):39–57
2010	Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008;34(1):86–96
2010	Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008;34(1):58–73
2011	Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009;35(5):515–524
2011	Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009;35(4):400–406
2012	Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” Semin Thromb Hemost 2010;36(1):59–70
2012	Rak J. Microparticles in cancer. Semin Thromb Hemost 2010;36(8):888–906
2013	Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost 2011;37(3):280–97
2013	Tufano A, Guida A, Dario Di Minno MN, Prisco D, Cerbone AM, Minno GD. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011;37(3):267–274
2014	Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012;38(1):23–30
2014	Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012;38(1):47–54
2014	Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Young G, Nowak-Göttl U. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost 2011;37(7):802–809
2015	Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost 2013;39(4):452–458
2015	George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost 2013;39(2):153–160
2015[a]	Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost 2013;39(2):147–152
2015[a]	Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013;39(2):117–126
2016	de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013;39(6):585–595
2016	Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014;40(4):416–421
2016[a]	Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012;38(7):673–682
2016[a]	Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 2014;40(1):60–65
2017	Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients. Semin Thromb Hemost 2015;41(1):68–74
2017	Levi M, Poll TV. Coagulation in patients with severe sepsis. Semin Thromb Hemost 2015;41(1):9–15
2017[a]	Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014;40(2):163–171
2017[a]	Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost 2015;41(1):49–60
2017[b]	Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost 2015;41(2):208–227
2018	Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet physiology. Semin Thromb Hemost 2016;42(3):191–204
2018	Mallett SV. Clinical utility of viscoelastic tests of coagulation (TEG/ROTEM) in patients with liver disease and during liver transplantation. Semin Thromb Hemost 2015;41(5):527–537
2018*	Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost 2015;41(4):395–404
2018*	Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 2014;40(1):106–114
2019	Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease. Semin Thromb Hemost 2018;44(4):353–363
2019	Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost 2017;43(3):331–337
2019*	Kell DB, Pretorius E. To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin? Semin Thromb Hemost 2018;44(3):224–238
2019*	Chighizola CB, Raimondo MG, Meroni PL. Management of thrombotic antiphospholipid syndrome. Semin Thromb Hemost 2018;44(5):419–426
2020	Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019;45(7):661–673
2020	Russo V, Attena E, Mazzone C, Esposito F, Parisi V, Bancone C, Rago A, Nigro G, Sangiuolo R, D' Onofrio A. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost 2018;44(4):364–369
2020*	Lippi G, Favaloro EJ, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports: epidemiology, causes, pathogenesis, and prevention. Semin Thromb Hemost 2018;44(8):780–786
2020*	Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. HYdroxychloroquine to improve pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017;43(6):562–571
2021	Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost 2020;46(1):89–95
2021	Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018;44(1):20–29
2021*	Gosselin RC, Adcock D, Dorgalaleh A, Favaloro EJ, Lippi G, Pego JM, Regan I, Siguret V. International Council for Standardization in Haematology recommendations for hemostasis critical values, tests, and reporting. Semin Thromb Hemost 2020;46(4):398–409
2021*	Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. Semin Thromb Hemost 2019;45(5):433–448
2022	Abildgaard A, Madsen SA, Hvas AM. Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin Thromb Hemost 2020;46(8):932–969
2022	Grottke O, Mallaiah S, Karkouti K, Saner F, Haas T. Fibrinogen supplementation and its indications. Semin Thromb Hemost 2020;46(1):38–49
2022*	Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020;46(7):763–771
2022*	Allaoui A, Khawaja AA, Badad O, Naciri M, Lordkipanidzé M, Guessous F, Zaid Y. Platelet function in viral immunity and SARS-CoV-2 infection. Semin Thromb Hemost 2021;47(4):419–426
2023	Branstetter JW, Kiskaddon AL, King MA, Coalter C, Grubbs KM, Fly H, Male C, Brandão L, Goldenberg NA. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in pediatric venous thromboembolism treatment and thromboprophylaxis: a systematic review of the literature. Semin Thromb Hemost 2021;47(6):643–653
2023	Ichinose A, Osaki T, Souri M. A review of coagulation abnormalities of autoimmune acquired factor V deficiency with a focus on Japan. Semin Thromb Hemost 2022;48(2):206–218
2023[a] [c]	Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022;48(1):8–14
2023[a]	Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, Jacquemin M, Janssens S, Lorent N, Liesenborghs L, Peerlinck K, Pieters G, Rex S, Sinonquel P, Van der Linden L, Van Laer C, Vos R, Wauters J, Wilmer A, Verhamme P, Vanassche T. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021;47(4):362–371.
2023[a]	Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021;47(4):372–391
2024[d]	Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022;48(8):978–987
2024	Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022;48(8):904–910
2024	Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug-drug interactions in the treatment of cancer-associated venous thromboembolism with direct oral anticoagulants. Semin Thromb Hemost 2024;50(3):489–498
2024[a]	Arachchillage DRJ, Pericleous C. Evolution of antiphospholipid syndrome. Semin Thromb Hemost 2023;49(3):295–304
2024[a]	Zidan A, Noureldin A, Kumar SA, Elsebaie A, Othman M. COVID-19 vaccine—associated immune thrombosis and thrombocytopenia (VITT): diagnostic discrepancies and global implications. Semin Thromb Hemost 2023;49(1):9–14

^a “Free access” category (first created in 2015).

^b This paper qualified as a “Most Popular” award winner based on objective publisher-provided download data; however, as this paper was co-written by the journal Editor in Chief, there was an obvious conflict of interest, and the award was officially declined. This paper is listed here merely as a statement of record.

^c This paper also qualified as a “Most Popular” award winner based on objective publisher-provided download data; however, as this paper was co-written by the journal Editor in Chief, there was a similar conflict of interest, and the monetary award was officially declined. This paper is again listed here merely as a statement of record.

^d This paper also qualified as a “Most Popular” award winner based on objective publisher-provided download data; however, Professor Iba indicated that as he previously won an award (in 2021), and since he had recently joined the STH Editorial Board, that he would decline the cash prize, and asked to pay this cash prize forward to enable another awardee, for which the publisher agreed (hence three awarded papers for this category in 2024).

There is also an increasingly recognized trend to publish articles under an open-access model, and these, as well as other freely available articles, will therefore have an “inequitable advantage” over other “nonopen access/nonfreely available” articles in terms of potential for downloads or perceived popularity due to their free accessibility. Accordingly, the publisher of STH has established separate categories of the Most Popular Award for “free access” papers (including open access) and an alternate “General Category” (nonfree access). Consequently, the most popular papers from each category are identified separately. [Tables 3] and [4] respectively list the top 30 downloaded articles from STH in 2024 (from 2023 and 2024 inclusive), as eligible for either the “free access” ([Table 3])[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] or “general category” ([Table 4])[31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] awards.

Table 3 Most popular papers—“free access” category[a]

Rank	Publication
1	Kruger A, Joffe D, Lloyd-Jones G, Khan MA, Salamon S, Laubscher GJ, Putrino D, Kell DB, Pretorius E. Vascular pathogenesis in acute and long COVID: Semin Thromb Hemost 2025;51:256–271
2	Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2023;49(6):621–633
3	Gosselin RC, Castellone D, Dorgalaleh A, Hickey K, Lippi G, Moffat K, O'Toole R, Rigano J. International Council for Standardization in Haematology guidance for new lot verification of coagulation reagents, calibrators, and controls. Semin Thromb Hemost 2024;50(8):1091–1102
4	Bowyer AE, Gosselin RC. Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments. Semin Thromb Hemost 2023;49(6):609–620
5	Luijten D, de Jong CMM, Ninaber MK, Spruit MA, Huisman MV, Klok FA. Post-pulmonary embolism syndrome and functional outcomes after acute pulmonary embolism. Semin Thromb Hemost 2023;49(8):848–860
6	Yong BSJ, Ling RR, Li R, Poh JW, Tan CS, Ho SWL, Rochwerg B, Arya R, Ramanathan K, Fan BE. Pharmacotherapy for venous thromboprophylaxis following total hip or knee arthroplasty: a systematic review and network meta-analysis. Semin Thromb Hemost 2025;51:290–300
7	Favaloro EJ. The role of the von Willebrand factor collagen-binding assay (VWF:CB) in the diagnosis and treatment of von Willebrand Disease (VWD) and way beyond: a comprehensive 36-year history. Semin Thromb Hemost 2024;50(1):43–80
8	Moore GW. Thrombophilia Screening: Not So Straightforward. Semin Thromb Hemost 2024;50(8):1131–1152
9	Ortega-Paz L, Talasaz AH, Sadeghipour P, Potpara TS, Aronow HD, Jara-Palomares L, Sholzberg M, Angiolillo DJ, Lip GYH, Bikdeli B. COVID-19-associated pulmonary embolism: a review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment. Semin Thromb Hemost 2023;49(8):816–832
10	Talasaz AH, McGonagle B, HajiQasemi M, Ghelichkhan ZA, Sadeghipour P, Rashedi S, Cuker A, Lech T, Goldhaber SZ, Jennings DL, Piazza G, Bikdeli B. Pharmacokinetic and pharmacodynamic interactions between food or herbal products and oral anticoagulants: evidence review, practical recommendations, and knowledge gaps. Semin Thromb Hemost 2024:10.1055/s-0044-1790258
11	Barcellona D, Marongiu F, Grandone E. Contraceptives and thrombosis: an intertwined revolutionary road. Semin Thromb Hemost 2024;50(1):91–95
12	Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023;49(5):444–452
13	Iba T, Wada H, Levy JH. Platelet activation and thrombosis in COVID-19. Semin Thromb Hemost 2023;49(1):55–61
14	Aguirre Del-Pino R, Monahan RC, Huizinga TWJ, Eikenboom J, Steup-Beekman GM. Risk factors for antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2024;50(6):817–828
15	Favaloro EJ. Evolution of hemostasis testing: a personal reflection covering over 40 years of history. Semin Thromb Hemost 2024;50(1):8–25
16	Pretorius E, Kell DB. A perspective on how fibrinaloid microclots and platelet pathology may be applied in clinical investigations. Semin Thromb Hemost 2024;50(4):537–551
17	Trujillo-Santos J, Demelo-Rodriguez P, Bravo de Laguna-Taboada A, Zubicoa-Ezpeleta S, Rodriguez-Morata A, Lojo-Rocamonde I, Riera-Mestre A; Working Group on for the Consensus on Venous Stenting. Optimizing venous stenting: consensus recommendations for enhanced management of lower extremity deep vein thrombosis. Semin Thromb Hemost 2024;50(6):883–893
18	Mabrouk M, Guessous F, Naya A, Merhi Y, Zaid Y. The pathophysiological role of platelet-derived extracellular vesicles. Semin Thromb Hemost 2023;49(3):279–283
19	Bissola AL, Zhang Y, Cranstone M, Moore JC, Warkentin TE, Arnold DM, Nazy I. Evaluating diagnostic algorithms for heparin-induced thrombocytopenia using two combined automated rapid immunoassays. Semin Thromb Hemost 2024;50(8):1123–1130
20	Franchini M, Cappello E, Valdiserra G, Bonaso M, Moretti U, Focosi D, Tuccori M. Investigating a signal of acquired hemophilia associated with COVID-19 vaccination: a systematic case review. Semin Thromb Hemost 2023;49(1):15–26
21	Buso G, Mazzolai L, Rueda-Camino JA, Fernandez-Capitan C, Jimenez D, Bikdeli B, Lobo JL, Fernandez-Reyes JL, Ciammaichella M, Monreal M; RIETE Investigators. Pulmonary embolism in patients with COVID-19: comparison between different care settings. Semin Thromb Hemost 2023;49(1):34–46
22	Lippi G, Favaloro EJ. What we know (and do not know) regarding the pathogenesis of pulmonary thrombosis in COVID-19. Semin Thromb Hemost 2023;49(1):27–33
23	Ichinose A, Osaki T, Souri M. Diagnosis and treatment of autoimmune acquired coagulation factor deficiencies: an evidence-based review of Japanese practice. Semin Thromb Hemost 2024:10.1055/s-0044-1787188
24	Al-Ghafry M, Abou-Ismail MY, Acharya SS. Inherited disorders of the fibrinolytic pathway: pathogenic phenotypes and diagnostic considerations of extremely rare disorders. Semin Thromb Hemost 2025;51:225–233
25	Rizk JG, Gupta A, Lazo JG Jr, Sardar P, Henry BM, Lavie CJ, Effron MB. To anticoagulate or not to anticoagulate in COVID-19: lessons after 2 years. Semin Thromb Hemost 2023;49(1):62–72
26	Arachchillage DJ, Kitchen S. Pleiotropic effects of heparin and its monitoring in the clinical practice. Semin Thromb Hemost 2024;50(8):1153–1162.
27	Arcani R, Cauchois R, Suchon P, Weber S, Jean R, Jarrot PA, Rey L, Venton G, Koubi M, Muller R, Bertin D, Mege JL, Kaplanski G, Bardin N. “True” antiphospholipid syndrome in COVID-19: contribution of the follow-up of antiphospholipid autoantibodies. Semin Thromb Hemost 2023;49(1):97–102
28	Candeloro M, Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis. Semin Thromb Hemost 2023;49(1):47–54
29	Spiezia L, Campello E, Tormene D, Simioni P. Venous thromboembolism in children: the rivaroxaban experience. Semin Thromb Hemost 2024;50(6):866–872
30	Warkentin TE. Limb ischemic necrosis secondary to microvascular thrombosis: a brief historical review. Semin Thromb Hemost 2024;50(5):760–772

^a 2023–2024 inclusive, as downloaded in 2024. Ranking is according to download data provided by journal publisher, and excludes nonqualifying material (e.g., Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, previous award-winning articles). Some papers qualified for this list as eFirst papers published in 2024; if available, citations have been updated using final 2025 citation.

Table 4 Most popular papers—“general” (nonfree access) category[a]

Rank	Publication
1	Bartlett R, Arachichilage DJ, Chitlur M, Hui SR, Neunert C, Doyle A, Retter A, Hunt BJ, Lim HS, Saini A, Renne T, Kostousov V, Teruya J. The History of Extracorporeal Membrane Oxygenation and the Development of Extracorporeal Membrane Oxygenation Anticoagulation. Semin Thromb Hemost 2024;50(1):81–90.
2	Costamagna G, Navi BB, Beyeler M, Hottinger AF, Alberio L, Michel P. Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment. Semin Thromb Hemost 2024;50(3):342–359.
3	Morrow GB, Mutch NJ. Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1). Semin Thromb Hemost 2023;49(3):305–313.
4	Larsen JB, Hvas AM, Hojbjerg JA. Platelet Function Testing: Update and Future Directions. Semin Thromb Hemost 2023;49(6):600–608.
5	Moser MM, Schoergenhofer C, Jilma B. Progress in von Willebrand Disease Treatment: Evolution toward Newer Therapies. Semin Thromb Hemost 2024;50(5):720–732.
6	Chandran R, Tohit ERM, Stanslas J, Salim N, Mahmood TMT, Rajagopal M. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment. Semin Thromb Hemost 2024;50(5):695–713.
7	Rashedi S, Greason CM, Sadeghipour P, Talasaz AH, O'Donoghue ML, Jimenez D, Monreal M, Anderson CD, Elkind MSV, Kreuziger LMB, Lang IM, Goldhaber SZ, Konstantinides SV, Piazza G, Krumholz HM, Braunwald E, Bikdeli B. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications. Semin Thromb Hemost 2024;50(5):773–789.
8	Adcock DM, Moore GW, Montalv√£o SL, Kershaw G, Gosselin RC. Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies: Current State of the Art. Semin Thromb Hemost 2023;49(6):571–579.
9	Bikdeli B, Sadeghipour P, Lou J, Bejjani A, Khairani CD, Rashedi S, Lookstein R, Lansky A, Vedantham S, Sobieszczyk P, Mena-Hurtado C, Aghayev A, Henke P, Mehdipoor G, Tufano A, Chatterjee S, Middeldorp S, Wasan S, Bashir R, Lang IM, Shishehbor MH, Gerhard-Herman M, Giri J, Menard MT, Parikh SA, Mazzolai L, Moores L, Monreal M, Jimenez D, Goldhaber SZ, Krumholz HM, Piazza G. Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review. Semin Thromb Hemost 2024;50(6):851–865.
10	Pruthi RK, Chen D. The Use of Bypassing Treatment Strategies in Hemophilia and Their Effect on Laboratory Testing. Semin Thromb Hemost 2023;49(6):651–660.
11	Levy-Mendelovich S, Cohen O, Klang E, Kenet G. 50 Years of Pediatric Hemostasis: Knowledge, Diagnosis, and Treatment. Semin Thromb Hemost 2023;49(3):217–224.
12	Betts MB, Liu X, Junqueira DR, Fahrbach K, Neupane B, Ronnebaum S, Dhamane AD. Risk of Venous Thromboembolism by Cancer Type: A Network Meta-Analysis. Semin Thromb Hemost 2024;50(3):328–341.
13	Kershaw G. Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents. Semin Thromb Hemost 2024;50(8):1163–1172.
14	Franchini M, Focosi D. Innovative Therapies for Acquired Hemophilia A. Semin Thromb Hemost 2025;51(1):68–72.
15	Saadalla A, Seheult J, Pruthi RK, Chen D. Von Willebrand Factor Multimer Analysis and Classification: A Comprehensive Review and Updates. Semin Thromb Hemost 2023;49(6):580–591.
16	Bala NS, Thornburg CD. Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives. Semin Thromb Hemost 2025;51:28–40.
17	Tufano A, Brenner B. Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: The Last 10 Years. Semin Thromb Hemost 2024;50(1):96–103.
18	Lippi G, Favaloro EJ. Pearls and Pitfalls in the Measurement of Direct Oral Anticoagulants. Semin Thromb Hemost 2024;50(8):1114–1122.
19	Dorgalaleh A. The History of Factor XIII Deficiency. Semin Thromb Hemost 2024;50(1):34–42.
20	Valerio L, Baddour LM. Septic Pulmonary Embolism: A Contemporary Profile. Semin Thromb Hemost 2023;49(8):840–847.
21	Woods AI, Paiva J, Dos Santos C, Alberto MF, Sanchez-Luceros A. From the Discovery of ADAMTS13 to Current Understanding of Its Role in Health and Disease. Semin Thromb Hemost 2023;49(3):284–294.
22	Giuffrida AC, Siboni SM, Baronciani L, Poli G, Gandini G, Peyvandi F. Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review. Semin Thromb Hemost 2025;51:73–80.
23	Ljung R. Prophylactic Treatment of Children with Hemophilia in Sweden. Semin Thromb Hemost 2024;50(5):714–719.
24	Nogami K. Clot Waveform Analysis for Monitoring Hemostasis. Semin Thromb Hemost 2023;49(6):592–599.
25	Warren BB, Moyer GC, Manco-Johnson MJ. Hemostasis in the Pregnant Woman, the Placenta, the Fetus, and the Newborn Infant. Semin Thromb Hemost 2023;49(4):319–329.
26	Iba T, Connors JM, Levy JH. What Role Does Microthrombosis Play in Long COVID? Semin Thromb Hemost 2024;50(4):527–536.
27	Willems RAL, Biesmans C, Campello E, Simioni P, de Laat B, de Vos-Geelen J, Roest M, Ten Cate H. Cellular Components Contributing to the Development of Venous Thrombosis in Patients with Pancreatic Cancer. Semin Thromb Hemost 2024;50(3):429–442.
28	Malinowski AK, Abdul-Kadir R. Planning Pregnancy and Birth in Women with Inherited Bleeding Disorders. Semin Thromb Hemost 2023;49(4):371–381.
29	Gelbenegger G, Buchtele N, Schoergenhofer C, Grafeneder J, Schwameis M, Schellongowski P, Denk W, Jilma B. Disseminated Intravascular Coagulation in Anaphylaxis. Semin Thromb Hemost 2024;50(4):569–579.
30	Andersson NG, Kenet G. Intracranial Hemorrhages in Neonates: Incidence, Risk Factors, and Treatment. Semin Thromb Hemost 2023;49(4):409–415.

^a 2023–2024 inclusive, as downloaded in 2024. Ranking is according to download data provided by journal publisher, and excludes nonqualifying material (e.g., Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, previous award-winning articles). Some papers qualified for this list as eFirst papers published in 2024; if available, citations have been updated using final 2025 citation.

Free Access Category[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30]

For recent prior awards, many of the most popular papers were related to COVID-19. As COVID-19 is no longer considered a pandemic, and as journals transition back to “business as usual,” COVID-19 papers have partly transitioned into post-COVID-19 or post-COVID-19 immunization-related papers. Thus, 10/30 papers in the top 30 list have some connection to COVID-19, with two of these related to vaccine-induced immune thrombotic thrombocytopenia (VITT),[2] [12] a rare but serious condition arising from vaccination against COVID-19 using adenovirus-based vaccine.

For the 2025 most popular awards, the top downloaded paper, was also related to COVID-19, being a review around “Long COVID,” otherwise alternatively called post-COVID-19 syndrome, long-haul COVID, postacute sequelae of COVID-19, by the authorship team of Kruger et al.[1] This paper has now been accessed online in excess of 25,000 times. This is even more extraordinary since the paper was published in 2024 and is still only available as an eFirst publication, being included in an issue to be published in 2025 (final citation in [Table 3]). The second most popular paper, from long-time collaborators Warkentin and Greinacher was related to VITT, and its “older cousin” heparin-induced thrombocytopenia (HIT).[2] Thus, the winners of the 2025 most popular awards for the “free access” category are:

1. Kruger A, Joffe D, Lloyd-Jones G, Khan MA, Salamon S, Laubscher GJ, Putrino D, Kell DB, Pretorius E. Vascular pathogenesis in acute and long COVID: current insights and therapeutic outlook. Semin Thromb Hemost 2024:10.1055/s-0044-1790603 (to be published as 2025;51:256–271).

2. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2023;49(6):621–633.

Several other eFirst papers also appear in [Table 3].[6] [10] [23] [24] This early recognition, before papers are published within an issue, should therefore be marked as a special achievement for these papers. Similarly, one of the listed papers derives from a previous Young Investigator award winner.[12]

General Category[31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60]

The publisher of STH, Thieme, had in the past provided most material related to COVID19 as free to download, and so COVID19 related material is less likely to be itemised in the “general category” list of most popular. The 30 most popular nonfree to download papers are listed in [Table 4]; thus, the two winners for this category are:

1. Bartlett R, Arachichilage DJ, Chitlur M, Hui SR, Neunert C, Doyle A, Retter A, Hunt BJ, Lim HS, Saini A, Renne T, Kostousov V, Teruya J. The history of extracorporeal membrane oxygenation and the development of extracorporeal membrane oxygenation anticoagulation. Semin Thromb Hemost 2024;50(1):81–90.

2. Costamagna G, Navi BB, Beyeler M, Hottinger AF, Alberio L, Michel P. Ischemic stroke in cancer: mechanisms, biomarkers, and implications for treatment. Semin Thromb Hemost 2024;50(3):342–359.

Again, several eFirst publications also appear in this list, with some of these just published in early 2025.[44] [46] [52]

As always, I always get considerable satisfaction in announcing these awards. In total, considering the top 30 papers in the “Free to download” most popular ([Table 3]) and the top 30 papers in the general category most popular ([Table 4]), the most popular issues (4 or more papers in [Tables 3] and [4]) were:

1. Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)-Part IV. Guest Editors: Favaloro EJ, Pasalic L, Lippi G.[61] (7 papers listed in [Tables 3] and [4])

2. Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part II. Guest Editors: Smock KJ, Gosselin RC.[62] (7 papers listed in [Tables 3] and [4])

3. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis-Part III.[63] Guest Editor: Favaloro EJ. (6 papers listed in [Tables 3] and [4])

4. Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part III.[64] Guest Editors: Smock KJ, Moffat KA (6 papers listed in [Tables 3] and [4])

5. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis-Part IV.[65] Guest Editor: Favaloro EJ. (5 papers listed in [Tables 3] and [4])

6. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis-Part II.[66] Guest Editor: Favaloro EJ. (4 papers listed in [Tables 3] and [4])

7. Recent Advances in Thrombosis and Hemostasis-Part X.[67] Guest Editor: Schulman S (4 papers listed in [Tables 3] and [4])

Other Popular Articles

Readers may also be interested to know what other papers were popular in 2024. [Table 5] provides a list of the 30 most popular papers published in STH before 2023. These papers also achieved high download status, but being published before 2023 do not qualify for the 2024 Most Popular Award. Indeed, many of the papers on this list actually represent past Most Popular Award-winning articles and are now freely available to download. Indeed, all the papers listed in [Table 5] are free to download from the publisher Web site (https://www.thieme-connect.de/products/ejournals/journal/10.1055/s-00000077), and the vast majority are previous most popular award-winning papers. However, a handful are not previous most popular award-winning papers; they include one previous Young Investigator paper, one Editorial, and a few other papers that probably missed just out on a prior award! As they are all free to download, it is likely that they will continue to appear on such “most popular” listings in future Editorials!

Table 5 Most popular papers in 2024 published before 2023[a]

Rank	Publication	Previous MP winner or other category?
1	Abildgaard A, Madsen SA, Hvas AM. Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin Thromb Hemost 2020;46(8):932–969	Y—2022
2	Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019;45(7):661–673	Y—2020
3	Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet physiology. Semin Thromb Hemost 2016;42(3):191–204	Y—2018
4	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005;31(4):381–392	Y—2009
5	Gosselin RC, Adcock D, Dorgalaleh A, Favaloro EJ, Lippi G, Pego JM, Regan I, Siguret V. International Council for Standardization in Haematology recommendations for hemostasis critical values, tests, and reporting. Semin Thromb Hemost 2020;46(4):398–409	Y—2021
6	Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost 2020;46(1):89–95	Y—2021
7	Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. Semin Thromb Hemost 2019;45(5):433–448	Y—2021
8	Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018;44(1):20–29	N (but separate ECMO paper won 2025 MP award)
9	Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” Semin Thromb Hemost 2010;36(1):59–70	Y—2012
10	Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost 2020;46(3):275–288	N
11	Grottke O, Mallaiah S, Karkouti K, Saner F, Haas T. Fibrinogen supplementation and its indications. Semin Thromb Hemost 2020;46(1):38–49	Y—2022
12	Tufano A, Brenner B. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: the last 10 years. Semin Thromb Hemost 2024;50(1):96–103	Y—2013
13	Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008;34(8):709–733	N
14	Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022;48(8):978–987	Y—2024
15	Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 2019;45(1):86–93	N—just missed out on 2021 MP award; from previous 2017 YIA
16	Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. Hydroxychloroquine to improve pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017;43(6):562–571	Y—2020
17	de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013;39(6):585–595	Y—2016
18	Rak J. Microparticles in cancer. Semin Thromb Hemost 2010;36(8):888–906	Y—2012
19	Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009;35(4):400–406	Y—2011
20	Lippi G, Salvagno GL, Gelati M, Poli G, Giavarina D, Favaloro EJ. Analytical assessment of the New Roche Cobas t 711 fully automated coagulation analyzer. Semin Thromb Hemost 2019;45(3):308–314	Y—2022
21	Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020;46(7):763–771	Y—2022
22	Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014;40(2):163–171	Y—2017
23	Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021;47(4):372–391	Y—2023
24	Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients. Semin Thromb Hemost 2015;41(1):68–74	Y—2017
25	Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012;38(7):673–682	Y—2016
26	Favaloro EJ. 2021 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. Semin Thromb Hemost 2022;48(3):265–273	N—Editorial
27	Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 2014;40(1):60–65	Y—2016
28	Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 Vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022;48(1):8–14	Y—2023
29	Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022;48(8):904–910	Y—2024
30	Levi M, Poll TV. Coagulation in patients with severe sepsis. Semin Thromb Hemost 2015;41(1):9–15	Y—2017

^a These papers were also highly downloaded in 2024, but were published before 2023, and so do not qualify for the 2025 Most Popular Awards. Most of these papers were prior Most Popular (MP) awards-winning articles (refer to [Table 2]). One was from a prior Young Investigator Award (YIA) winner. One was an Editorial, which does not qualify for any awards, but validates our publication of these Editorials!

Responses from Award Winners

All authors of the award-winning articles were thrilled to hear that their papers had won an Eberhard F Mammen Most Popular award and provided their own personal responses to the news.

“From Etheresia (Resia) Pretorius, on behalf of all authors ([Fig. 2]), “We are honored and deeply gratified to receive the Eberhard F. Mammen Seminars in Thrombosis and Hemostasis Most Popular Article Award in the “Free to Download” category for our article, “Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook.” The recognition underscores the importance of addressing vascular dysfunction as a central theme in the pathophysiology of long COVID, a topic that resonates deeply within the current global health landscape and holds critical significance for patients urgently seeking effective treatments.

Fig. 2 From left to right, top to bottom: Arneaux Kruger, David Joffe, Graham Lloyd-Jones, Muhammed Asad Khan, Špela Šalamon, Gert J. Laubscher, David Putrino, Douglas B. Kell, Etheresia Pretorius.

Our review highlights the pivotal role of thrombotic endothelialitis in both acute and long COVID, emphasizing the necessity for early diagnostic and therapeutic strategies to mitigate endothelial dysfunction and its systemic consequences. This award is a testament to the collaborative efforts of an exceptional research team spanning multiple disciplines and institutions across the globe.

We also extend our deepest gratitude to the readers and editorial board STH for recognizing our work's relevance and significance. This acknowledgment motivates us to continue our efforts in elucidating the complexities of long COVID and advancing our understanding of vascular pathogenesis for better patient outcomes.

Thank you for this incredible honor.”

From Ted Warkentin and Andreas Greinacher ([Fig. 3]), “We're so very glad to hear that the readers of STH were interested in our review of laboratory testing for HIT and VITT antibodies. Although not known at the time of its publication, subsequent discoveries that VITT/VITT-like antibodies can be caused by adenovirus infection and also be synonymous with certain platelet-activating monoclonal gammopathies (VITT-like monoclonal gammopathy of thrombotic significance), means that this topic will remain relevant, even as classic (vaccine-induced) VITT has become a thing of the past.”

Fig. 3 Left to right: Theodore E. Warkentin, Andreas Greinacher.

From Jun Teruya, on behalf of all authors, many of whom provided photos for this announcement ([Fig. 4]): “We are thrilled to have received an Eberhard F Mammen Seminars in Thrombosis and Hemostasis Most Popular Article Award in the General Category. This is the second time I have personally been honored with this award. When Prof. Favaloro asked me to write about the history of extracorporeal membrane oxygenation (ECMO), I immediately reached out to Dr. Robert Bartlett, the Father of ECMO. He happily accepted my invitation to be the first author. It was fortunate that a total of 13 world experts in various areas of ECMO eventually contributed to this article. Until I began working at Texas Children's Hospital in 2001, I had no experience with ECMO. However, soon after I started observing ECMO, I became very interested in managing coagulation, anticoagulation, and transfusion. It is a complex and fascinating model of coagulation and platelets. Since the inception of ECMO, there have been numerous technological developments and improvements in patient outcomes as stated in the article. I hope to author a similar article on the history of ECMO in 10 years. I am confident that the complications of bleeding and thrombosis will be much less prevalent by then.”

Fig. 4 From left to right, top to bottom: Jun Teruya (with a baby who was on ECMO and received a successful heart transplant; permission obtained from the patient's family), Deepa J. Arachichilage, Meera Chitlur, Shiu-Ki Rocky Hui, Cindy Neunert, Andrew Doyle, Beverley J. Hunt, Hoong Sem Lim, Arun Saini, Thomas Renné, Vadim Kostousov (missing: Robert Bartlett, Andrew Retter).

From Gianluca Costamagna and Patrik Michel ([Fig. 5]), speaking on behalf of all authors, “We are deeply honored to receive one of the 2025 Eberhard F. Mammen Seminars in Thrombosis and Hemostasis Most Popular Article Awards. We are happy to learn that our narrative review, “Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment,” has been so well-received by the readership.

Fig. 5 left to right: Gianluca Costamagna, Patrik Michel (missing: Babak B. Navi, Morin Beyeler, Andreas F. Hottinger, Lorenzo Alberio).

Cancer-related stroke is a niche yet relevant topic within the vascular neurology and hematology communities, often involving critically ill patients managed with limited evidence-based guidelines. In our review, we discussed the underlying pathophysiology and proposed a new framework for classifying cancer-related mechanisms. We also overviewed available biomarkers, highlighting their associations with outcomes, and provided a detailed discussion on current evidence for acute-phase treatments in this population. Additionally, we addressed the selection of antithrombotic therapy at discharge, as well as considerations for initiating or resuming cancer treatment after stroke. We extend our thanks to the Editor-in-Chief, Prof. Favaloro, for the opportunity to review this important topic, and to all our co-authors for their invaluable contributions.”

I would, as always, like to thank not only all the authors listed in [Tables 2] [3] [4] [5], but also all the other contributing authors that didn't manage to make these listings, as well as all the many other guest editors of issues recently published in STH. I likewise look forward to seeing future listings—always a great pleasure and sometimes a surprise.

Conflict of Interest

None declared.

• References

• 1 Kruger A, Joffe D, Lloyd-Jones G. et al. Vascular pathogenesis in acute and long COVID: current insights and therapeutic outlook. Semin Thromb Hemost 2024; 51: 256-271
• 2 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2023; 49 (06) 621-633
• 3 Gosselin RC, Castellone D, Dorgalaleh A. et al. International Council for Standardization in Haematology guidance for new lot verification of coagulation reagents, calibrators, and controls. Semin Thromb Hemost 2024; 50 (08) 1091-1102
• 4 Bowyer AE, Gosselin RC. Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments. Semin Thromb Hemost 2023; 49 (06) 609-620
• 5 Luijten D, de Jong CMM, Ninaber MK, Spruit MA, Huisman MV, Klok FA. Post-pulmonary embolism syndrome and functional outcomes after acute pulmonary embolism. Semin Thromb Hemost 2023; 49 (08) 848-860
• 6 Yong BSJ, Ling RR, Li R. et al. Pharmacotherapy for venous thromboprophylaxis following total hip or knee arthroplasty: a systematic review and network meta-analysis. Semin Thromb Hemost 2024; 51: 290-300
• 7 Favaloro EJ. The role of the von Willebrand factor collagen-binding assay (VWF:CB) in the diagnosis and treatment of von Willebrand disease (VWD) and way beyond: a comprehensive 36-year history. Semin Thromb Hemost 2024; 50 (01) 43-80
• 8 Moore GW. Thrombophilia screening: not so straightforward. Semin Thromb Hemost 2024; 50 (08) 1131-1152
• 9 Ortega-Paz L, Talasaz AH, Sadeghipour P. et al. COVID-19-associated pulmonary embolism: review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (08) 816-832
• 10 Talasaz AH, McGonagle B, HajiQasemi M. et al. Pharmacokinetic and pharmacodynamic interactions between food or herbal products and oral anticoagulants: evidence review, practical recommendations, and knowledge gaps. Semin Thromb Hemost 2024;
• 11 Barcellona D, Marongiu F, Grandone E. Contraceptives and thrombosis: an intertwined revolutionary road. Semin Thromb Hemost 2024; 50 (01) 91-95
• 12 Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023; 49 (05) 444-452
• 13 Iba T, Wada H, Levy JH. Platelet activation and thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 55-61
• 14 Aguirre Del-Pino R, Monahan RC, Huizinga TWJ, Eikenboom J, Steup-Beekman GM. Risk factors for antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2024; 50 (06) 817-828
• 15 Favaloro EJ. Evolution of hemostasis testing: a personal reflection covering over 40 years of history. Semin Thromb Hemost 2024; 50 (01) 8-25
• 16 Pretorius E, Kell DB. A perspective on how fibrinaloid microclots and platelet pathology may be applied in clinical investigations. Semin Thromb Hemost 2024; 50 (04) 537-551
• 17 Trujillo-Santos J, Demelo-Rodríguez P, Bravo de Laguna-Taboada A. et al; Working Group on for the Consensus on Venous Stenting. Optimizing venous stenting: consensus recommendations for enhanced management of lower extremity deep vein thrombosis. Semin Thromb Hemost 2024; 50 (06) 883-893
• 18 Mabrouk M, Guessous F, Naya A, Merhi Y, Zaid Y. The pathophysiological role of platelet-derived extracellular vesicles. Semin Thromb Hemost 2023; 49 (03) 279-283
• 19 Bissola AL, Zhang Y, Cranstone M. et al. Evaluating diagnostic algorithms for heparin-induced thrombocytopenia using two combined automated rapid immunoassays. Semin Thromb Hemost 2024; 50 (08) 1123-1130
• 20 Franchini M, Cappello E, Valdiserra G. et al. Investigating a signal of acquired hemophilia associated with COVID-19 vaccination: a systematic case review. Semin Thromb Hemost 2023; 49 (01) 15-26
• 21 Buso G, Mazzolai L, Rueda-Camino JA. et al; RIETE Investigators. Pulmonary embolism in patients with COVID-19: comparison between different care settings. Semin Thromb Hemost 2023; 49 (01) 34-46
• 22 Lippi G, Favaloro EJ. What we know (and do not know) regarding the pathogenesis of pulmonary thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 27-33
• 23 Ichinose A, Osaki T, Souri M. Diagnosis and treatment of autoimmune acquired coagulation factor deficiencies: an evidence-based review of Japanese practice. Semin Thromb Hemost 2024;
• 24 Al-Ghafry M, Abou-Ismail MY, Acharya SS. Inherited disorders of the fibrinolytic pathway: pathogenic phenotypes and diagnostic considerations of extremely rare disorders. Semin Thromb Hemost 2025; 51: 225-233
• 25 Rizk JG, Gupta A, Lazo Jr JG. et al. To anticoagulate or not to anticoagulate in COVID-19: lessons after 2 years. Semin Thromb Hemost 2023; 49 (01) 62-72
• 26 Arachchillage DJ, Kitchen S. Pleiotropic effects of heparin and its monitoring in the clinical practice. Semin Thromb Hemost 2024; 50 (08) 1153-1162
• 27 Arcani R, Cauchois R, Suchon P. et al. “True” antiphospholipid syndrome in COVID-19: contribution of the follow-up of antiphospholipid autoantibodies. Semin Thromb Hemost 2023; 49 (01) 97-102
• 28 Candeloro M, Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis. Semin Thromb Hemost 2023; 49 (01) 47-54
• 29 Spiezia L, Campello E, Tormene D, Simioni P. Venous thromboembolism in children: the rivaroxaban experience. Semin Thromb Hemost 2024; 50 (06) 866-872
• 30 Warkentin TE. Limb ischemic necrosis secondary to microvascular thrombosis: a brief historical review. Semin Thromb Hemost 2024; 50 (05) 760-772
• 31 Bartlett R, Arachichilage DJ, Chitlur M. et al. The history of extracorporeal membrane oxygenation and the development of extracorporeal membrane oxygenation anticoagulation. Semin Thromb Hemost 2024; 50 (01) 81-90
• 32 Costamagna G, Navi BB, Beyeler M, Hottinger AF, Alberio L, Michel P. Ischemic stroke in cancer: mechanisms, biomarkers, and implications for treatment. Semin Thromb Hemost 2024; 50 (03) 342-359
• 33 Morrow GB, Mutch NJ. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Semin Thromb Hemost 2023; 49 (03) 305-313
• 34 Larsen JB, Hvas AM, Hojbjerg JA. Platelet function testing: update and future directions. Semin Thromb Hemost 2023; 49 (06) 600-608
• 35 Moser MM, Schoergenhofer C, Jilma B. Progress in von Willebrand disease treatment: evolution towards newer therapies. Semin Thromb Hemost 2024; 50 (05) 720-732
• 36 Chandran R, Tohit ERM, Stanslas J, Salim N, Mahmood TMT, Rajagopal M. Shifting paradigms and arising concerns in severe hemophilia A treatment. Semin Thromb Hemost 2024; 50 (05) 695-713
• 37 Rashedi S, Greason CM, Sadeghipour P. et al. Fibrinolytic agents in thromboembolic diseases: historical perspectives and approved indications. Semin Thromb Hemost 2024; 50 (05) 773-789
• 38 Adcock DM, Moore GW, Montalvão SL, Kershaw G, Gosselin RC. Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art. Semin Thromb Hemost 2023; 49 (06) 571-579
• 39 Bikdeli B, Sadeghipour P, Lou J. et al. Developmental or procedural vena cava interruption and venous thromboembolism: a review. Semin Thromb Hemost 2024; 50 (06) 851-865
• 40 Pruthi RK, Chen D. The use of bypassing treatment strategies in hemophilia and their effect on laboratory testing. Semin Thromb Hemost 2023; 49 (06) 651-660
• 41 Levy-Mendelovich S, Cohen O, Klang E, Kenet G. 50 years of pediatric hemostasis: knowledge, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (03) 217-224
• 42 Betts MB, Liu X, Junqueira DR. et al. Risk of venous thromboembolism by cancer type: a network meta-analysis. Semin Thromb Hemost 2024; 50 (03) 328-341
• 43 Kershaw G. Strategies for performing factor assays in the presence of emicizumab or other novel/emerging hemostatic agents. Semin Thromb Hemost 2024; 50 (08) 1163-1172
• 44 Franchini M, Focosi D. Innovative therapies for acquired hemophilia A. Semin Thromb Hemost 2025; 51 (01) 68-72
• 45 Saadalla A, Seheult J, Pruthi RK, Chen D. Von Willebrand factor multimer analysis and classification: a comprehensive review and updates. Semin Thromb Hemost 2023; 49 (06) 580-591
• 46 Bala NS, Thornburg CD. Gene therapy in hemophilia A: achievements, challenges, and perspectives. Semin Thromb Hemost 2025; 51 (01) 28-40
• 47 Tufano A, Brenner B. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: the last 10 years. Semin Thromb Hemost 2024; 50 (01) 96-103
• 48 Lippi G, Favaloro EJ. Pearls and pitfalls in the measurement of direct oral anticoagulants. Semin Thromb Hemost 2024; 50 (08) 1114-1122
• 49 Dorgalaleh A. The history of factor XIII deficiency. Semin Thromb Hemost 2024; 50 (01) 34-42
• 50 Valerio L, Baddour LM. Septic pulmonary embolism: a contemporary profile. Semin Thromb Hemost 2023; 49 (08) 840-847
• 51 Woods AI, Paiva J, Dos Santos C, Alberto MF, Sánchez-Luceros A. From the discovery of ADAMTS13 to current understanding of its role in health and disease. Semin Thromb Hemost 2023; 49 (03) 284-294
• 52 Giuffrida AC, Siboni SM, Baronciani L, Poli G, Gandini G, Peyvandi F. Emicizumab in type 3 von Willebrand disease: report of a case with an alloantibody and literature review. Semin Thromb Hemost 2025; 51 (01) 73-80
• 53 Ljung R. Prophylactic treatment of children with hemophilia in Sweden. Semin Thromb Hemost 2024; 50 (05) 714-719
• 54 Nogami K. Clot waveform analysis for monitoring hemostasis. Semin Thromb Hemost 2023; 49 (06) 592-599
• 55 Warren BB, Moyer GC, Manco-Johnson MJ. Hemostasis in the pregnant woman, the placenta, the fetus, and the newborn infant. Semin Thromb Hemost 2023; 49 (04) 319-329
• 56 Iba T, Connors JM, Levy JH. What role does microthrombosis play in long COVID?. Semin Thromb Hemost 2024; 50 (04) 527-536
• 57 Willems RAL, Biesmans C, Campello E. et al. Cellular components contributing to the development of venous thrombosis in patients with pancreatic cancer. Semin Thromb Hemost 2024; 50 (03) 429-442
• 58 Malinowski AK, Abdul-Kadir R. planning pregnancy and birth in women with inherited bleeding disorders. Semin Thromb Hemost 2023; 49 (04) 371-381
• 59 Gelbenegger G, Buchtele N, Schoergenhofer C. et al. Disseminated intravascular coagulation in anaphylaxis. Semin Thromb Hemost 2024; 50 (04) 569-579
• 60 Andersson NG, Kenet G. Intracranial hemorrhages in neonates: incidence, risk factors, and treatment. Semin Thromb Hemost 2023; 49 (04) 409-415
• 61 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
• 62 Smock KJ, Gosselin RC. Laboratory diagnostics for thrombosis and hemostasis testing-part II. Semin Thromb Hemost 2023; 49 (06) 569-570
• 63 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part III. Semin Thromb Hemost 2024; 50 (01) 4-7
• 64 Smock KJ, Moffat KA. Laboratory diagnostics for thrombosis and hemostasis testing-part III. Semin Thromb Hemost 2024; 50 (08) 1047-1048
• 65 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part IV. Semin Thromb Hemost 2024; 50 (05) 677-681
• 66 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part II. Semin Thromb Hemost 2023; 49 (03) 212-216
• 67 Schulman S. Recent advances in thrombosis and hemostasis-part X. Semin Thromb Hemost 2024; 50 (06) 807-808

Publikationsverlauf

Artikel online veröffentlicht:
25. März 2025